Shanghai Claison Biotechnology

Shanghai Claison Biotechnology is a Chinese biotechnology company primarily focused on the development and commercialization of cellular immunotherapies for oncology. Founded in 2014, the company specializes in dendritic cell (DC) and cytokine-induced killer (CIK) cell technologies, as well as natural killer (NK) cell therapies. Claison gained significant public attention in China due to its involvement as a technology provider for therapies used in the Wei Zexi incident, which led to stricter regulations on cell therapy in the country. Despite regulatory shifts, the company continues to work on advanced cell-based treatments for various solid tumors and hematological cancers. Its operations are centered in Shanghai, where it maintains research and manufacturing facilities.